We recently published this summary of our good intentions to (i) improve systematic follow-up using simple tools, (ii) listen to the feedback of pwMS and (iii) develop a yet closer collaboration with the MS Society’s UK MS Register (). Conceived well before the pandemic broke out, the concept of “assisted self-monitoring” developed new urgency in the light of #MSCOVID-19. The...
Skin reactions with cladribine
Since 2014, i.e. three years before cladribine tablets were EMA licensed for highly active MS, we have treated well over 200 pwMS using injectable (s.c.) cladribine as an off-label immunotherapy. This has been a well received programme that helped a number of pwMS access treatment, who were either not eligible for licensed disease-modifying treatments (DMT), or chose our off-label offering over...
#MSCOVID19 – Updated ABN guidance on MS DMT during the pandemic
Thanks to @drruthdobson I’ve just received the new ABN guidance on MS disease modifying treatment during the COVID-19 crisis. This updates last week’s document shared here: . ABN-Guidance-on-DMTs-for-MS-and-COVID19-APPROVED-18-March-v-3 The main change is related to NHS England having relaxed the eligibility criteria for natalizumab (Tysabri) in order to enable using the drug instead...
#COVIDMS ABN guidance on DMT in the times of COVID-19
Here it is, hot off the pdf, and now you may be really confused, but that’s the nature of debate, and the Blog doesn’t (always) provide medical advice you should translate 1:1 into your own disease management, so take it with a pinch of salt and discuss your individual risk-benefit profile with your care team. ABN-Guidance-on-DMTs-for-MS-and-COVID19-APPROVED-11-March Fortunately...
#ThinkHand – What happened to #ChariotMS ?
Yes, what happened you might ask, and all I can say is: A great deal. The UK National Institute of Health Research’s EME board has elevated #ChariotMS from the brawling crowd (stage 1) to the boxing ring (stage 2), and the reason they gave was this: “The Board note that this is an important research question.” No further patting on the back though, since the whole team is...
World MS Day 2018
It’s World MS Day today! This annual awareness day has been pioneered by the MS International Foundation (MSIF) and takes place each year at the end of May. Check here for events across the Globe. This years’s World MS Day campaign headline is #bringinguscloser, which the organisers translate as follows: “Research is bringing us closer to ending MS. To...
ACTRIMS 2018: Rituximab does not affect MRI detected meningeal lesions
Intrathecal rituximab is worth exploring as a treatment option? Can it eliminate the B-cells driving progressive disease? Phase 1 Trial of Intrathecal Rituximab in Progressive MS Patients with Evidence of Leptomeningeal Contrast Enhancement Background: Leptomeningeal inflammation is associated with increased cortical demyelination, neuronal damage and worse clinical outcomes, suggesting it may...
Here comes #ChariotMS. Or does it?
Is the #ChariotMS study worth funding? Is upper limb function worth saving in people with more advanced MS? The objectives of our #ThinkHand awareness event, which we are hosting this Thursday night, is to celebrate hand function in people with MS and to promote #ChariotMS to the wider community. It’s all about you. Do you believe #ChariotMS is worthwhile supporting? Should some of the...
#ChariotMS – Time for action
The latest news from our #ChariotMS Project Chariot ms 4_ms-society_feb2018_4_slsh from Klaus Schmierer For some time we have been talking about this trial which builds on a number of recent insights we feel quite strongly about. They are not only our own insights, of course; others have thought and worked hard too, and this becomes no less evident than by reading the list of collaborators, and...
Another eagle? No – a Maven has landed !
It’s official now, oral cladribine (Mavenclad) has just been given the nod by the EU Commission. Whatever the somewhat clumsy detail of the license, and wherever the ensueing discussions with funders will lead on the ground, this is excellent news. Big congratulations to Merck KgA for resurrecting their cladribine programme after BartsMS had started their own given the excellent data...